<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36213654</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence.</ArticleTitle><Pagination><StartPage>1003103</StartPage><MedlinePgn>1003103</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1003103</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2022.1003103</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC) in &#x223c;30% of all infected individuals. Here, we present a case of PASC in a patient with rheumatoid arthritis characterized by viral persistence in the nasopharynx for 6 months after acute infection. We demonstrate transient disappearance of antigen persistence and decreased antiviral and autoimmune T cell responses after nirmatrelvir/ritonavir and tocilizumab treatment.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="UNASSIGNED">A 37-year-old female with a 7-year history of rheumatoid arthritis enrolled in a COVID-19 research study was found to continuously test SARS-CoV-2 antigen positive in the nasopharynx for 6 months after acute infection. She simultaneously presented with new-onset PASC symptoms including chronic occipital headache and periods of intense fatigue 8 weeks after acute infection. The patient was prescribed nirmatrelvir/ritonavir to treat SARS-CoV-2 persistence at 3.5 months post-acute infection and observed a reduction in PASC symptoms 3 weeks after completing antiviral treatment. After resurgence of PASC symptoms, she stopped treatment with tocilizumab for rheumatoid arthritis to attempt complete SARS-CoV-2 viral clearance. The severity of the patient's PASC symptoms subsequently increased, and she developed new-onset brain fog in addition to previous symptoms, which resolved after resumption of tocilizumab treatment. Assessment of adaptive immune responses demonstrated that nirmatrelvir/ritonavir and tocilizumab treatment decreased antiviral and autoreactive T cell activation. After resuming tocilizumab treatment, the patient's PASC symptoms were significantly reduced, but nasopharyngeal antigen positivity remained.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">These data suggest that nirmatrelvir/ritonavir should be considered in the treatment of PASC in patients who have SARS-CoV-2 antigen persistence, though care must be taken to monitor the patient for symptom resurgence or viral reactivation. In addition, the IL-6 inhibitor tocilizumab may ameliorate PASC symptoms in patients with persistent headache, fatigue, and brain fog.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Visvabharathy, Orban and Koralnik.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Visvabharathy</LastName><ForeName>Lavanya</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orban</LastName><ForeName>Zachary S</ForeName><Initials>ZS</Initials><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koralnik</LastName><ForeName>Igor J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">case report</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">nirmatrelvir/ritonavir</Keyword><Keyword MajorTopicYN="N">tocilizumab</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>10</Day><Hour>4</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36213654</ArticleId><ArticleId IdType="pmc">PMC9537824</ArticleId><ArticleId IdType="doi">10.3389/fmed.2022.1003103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Johns Hopkins Coronavirus Resource Center. Cumulative Worldwide Covid-19 Cases. Baltimore, MD: Johns Hopkins University of Medicine; (2021).</Citation></Reference><Reference><Citation>Graham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 &#x201c;long haulers&#x201d;. Ann Clin Transl Neurol. (2021) 8:1073&#x2013;85. 10.1002/acn3.51350</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51350</ArticleId><ArticleId IdType="pmc">PMC8108421</ArticleId><ArticleId IdType="pubmed">33755344</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins V, Sohaei D, Diamandis EP, Prassas I. COVID-19: From an acute to chronic disease? Potential long-term health consequences. Crit Rev Clin Lab Sci. (2020). 58, 297&#x2013;310. 10.1080/10408363.2020.1860895</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408363.2020.1860895</ArticleId><ArticleId IdType="pubmed">33347790</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman J, Thakur N, Peacock TP, Bialy D, Elrefaey AME, Bogaardt C, et al. Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2. Nat Microbiol. (2022) 7:1180&#x2013;8. 10.1038/s41564-022-01163-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01163-3</ArticleId><ArticleId IdType="pmc">PMC9352594</ArticleId><ArticleId IdType="pubmed">35836002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al. Persistent symptoms after Covid-19: qualitative study of 114 &#x201c;long Covid&#x201d; patients and draft quality principles for services. BMC Health Serv Res. (2020) 20:1144. 10.1186/s12913-020-06001-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-020-06001-y</ArticleId><ArticleId IdType="pmc">PMC7750006</ArticleId><ArticleId IdType="pubmed">33342437</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghimi N, Di Napoli M, Biller J, Siegler JE, Shekhar R, McCullough LD, et al. The Neurological manifestations of post-acute sequelae of SARS-CoV-2 infection. Curr Neurol Neurosci Rep. (2021) 21:44. 10.1007/s11910-021-01130-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-021-01130-1</ArticleId><ArticleId IdType="pmc">PMC8237541</ArticleId><ArticleId IdType="pubmed">34181102</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. (2021) 27:601&#x2013;15. 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham EL, Koralnik IJ, Liotta EM. Therapeutic Approaches to the Neurologic Manifestations of COVID-19. Neurotherapeutics. (2022) [Epub ahead of print]. 10.1007/s13311-022-01267-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01267-y</ArticleId><ArticleId IdType="pmc">PMC9302225</ArticleId><ArticleId IdType="pubmed">35861926</ArticleId></ArticleIdList></Reference><Reference><Citation>Havenar-Daughton C, Reiss SM, Carnathan DG, Wu JE, Kendric K, Torrents de la Pena A, et al. Cytokine-independent detection of antigen-specific germinal center t follicular helper cells in immunized nonhuman primates using a live cell activation-induced marker technique. J Immunol. (2016) 197:994&#x2013;1002. 10.4049/jimmunol.1600320</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1600320</ArticleId><ArticleId IdType="pmc">PMC4955744</ArticleId><ArticleId IdType="pubmed">27335502</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschtick JL, Titus AR, Slocum E, Power LE, Hirschtick RE, Elliott MR, et al. Population-based estimates of post-acute sequelae of SARS-CoV-2 infection (PASC) prevalence and characteristics. Clin Infect Dis. (2021) 73:2055&#x2013;64. 10.1093/cid/ciab408</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab408</ArticleId><ArticleId IdType="pmc">PMC8240848</ArticleId><ArticleId IdType="pubmed">34007978</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, et al. Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA. (2021) 325:2015&#x2013;6. 10.1001/jama.2021.5612</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.5612</ArticleId><ArticleId IdType="pmc">PMC8027932</ArticleId><ArticleId IdType="pubmed">33825846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed H, Patel K, Greenwood DC, Halpin S, Lewthwaite P, Salawu A, et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and middle east respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis. J Rehabil Med. (2020) 52:jrm00063.</Citation><ArticleIdList><ArticleId IdType="pubmed">32449782</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari A, Trevenzoli M, Sasset L, Di Liso E, Tavian T, Rossi L, et al. Prolonged SARS-CoV-2-RNA detection from nasopharyngeal swabs in an oncologic patient: What impact on cancer treatment? Curr Oncol. (2021) 28:847&#x2013;52. 10.3390/curroncol28010083</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/curroncol28010083</ArticleId><ArticleId IdType="pmc">PMC7985795</ArticleId><ArticleId IdType="pubmed">33567626</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, Zlitni S, Brooks EF, Vance SE, Dahlen A, Hedlin H, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med. (2022) 3:371&#x2013;387.e9. 10.1016/j.medj.2022.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornton CS, Huntley K, Berenger BM, Bristow M, Evans DH, Fonseca K, et al. Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values. Antimicrob Resist Infect Control. (2022) 11:28. 10.1186/s13756-022-01067-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13756-022-01067-1</ArticleId><ArticleId IdType="pmc">PMC8817557</ArticleId><ArticleId IdType="pubmed">35123573</ArticleId></ArticleIdList></Reference><Reference><Citation>Snow TAC, Saleem N, Ambler G, Nastouli E, Singer M, Arulkumaran N. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials. Intensive Care Med. (2021) 47:641&#x2013;52. 10.1007/s00134-021-06416-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-021-06416-z</ArticleId><ArticleId IdType="pmc">PMC8139226</ArticleId><ArticleId IdType="pubmed">34019122</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19a meta-analysis. Ann Med. (2022) 54:516&#x2013;23. 10.1080/07853890.2022.2034936</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2034936</ArticleId><ArticleId IdType="pmc">PMC8820829</ArticleId><ArticleId IdType="pubmed">35118917</ArticleId></ArticleIdList></Reference><Reference><Citation>Boucau J, Uddin R, Marino C, Regan J, Flynn JP, Choudhary MC, et al. Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for COVID-19. Clin Infect Dis. (2022) [Epub ahead of print]. 10.1093/cid/ciac512</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac512</ArticleId><ArticleId IdType="pmc">PMC9384370</ArticleId><ArticleId IdType="pubmed">35737946</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022. medRxiv [Preprint]. (2022) 10.1101/2022.06.21.22276724</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.21.22276724</ArticleId><ArticleId IdType="pmc">PMC9258292</ArticleId><ArticleId IdType="pubmed">35794889</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. (2022) 23:210&#x2013;6. 10.1038/s41590-021-01113-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappelmann N, Dantzer R, Khandaker GM. Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. Psychoneuroendocrinology. (2021) 131:105295. 10.1016/j.psyneuen.2021.105295</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2021.105295</ArticleId><ArticleId IdType="pmc">PMC8172271</ArticleId><ArticleId IdType="pubmed">34119855</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuwa HA, Shaw TN, Knight SB, Wemyss K, McClure FA, Pearmain L, et al. Alterations in T and B cell function persist in convalescent COVID-19 patients. Med. (2021) 2:720&#x2013;735.e4. 10.1016/j.medj.2021.03.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2021.03.013</ArticleId><ArticleId IdType="pmc">PMC8011689</ArticleId><ArticleId IdType="pubmed">33821250</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. (2022) 10:761&#x2013;75. 10.1016/S2213-2600(22)00127-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00127-8</ArticleId><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Visvabharathy L, Hanson B, Orban Z, Lim PH, Palacio NM, Jain R, et al. Neuro-COVID long-haulers exhibit broad dysfunction in T cell memory generation and responses to vaccination. medRxiv [Preprint]. (2021) 10.1101/2021.08.08.21261763</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.08.08.21261763</ArticleId><ArticleId IdType="pmc">PMC8366804</ArticleId><ArticleId IdType="pubmed">34401886</ArticleId></ArticleIdList></Reference><Reference><Citation>Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology. (2013) 52:53&#x2013;61. 10.1093/rheumatology/kes305</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kes305</ArticleId><ArticleId IdType="pubmed">23192911</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T, Masuko-Hongo K, Matsui T, Asahara H, Takigawa M, Nishioka K, et al. Recognition of YKL-39, a human cartilage related protein, as a target antigen in patients with rheumatoid arthritis. Ann Rheum Dis. (2001) 60:49&#x2013;54. 10.1136/ard.60.1.49</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.60.1.49</ArticleId><ArticleId IdType="pmc">PMC1753367</ArticleId><ArticleId IdType="pubmed">11114282</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. (2022) 28:1461&#x2013;7. 10.1038/s41591-022-01840-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, et al. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA. (2022) 328:676. 10.1001/jama.2022.11691</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.11691</ArticleId><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>